Abstract
A total of 192 children and adolescents undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS, n = 93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B, n = 99). Six-month outcome data have previously been reported; this manuscript reports the 2-year data. Complete 2-year data were available on 164 (85.4%) of the original 192 patients. There was a single death in the TAS arm. Kaplan–Meier estimates of survival free of graft loss at 2 years were 94.9% in the TAS + B arm and 89.6% in the TAS arm [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.17 to 1.54, P = 0.23]. Estimates of survival free from rejection at 2 years were 75.2% in the TAS + B arm and 68.7% in the TAS arm (HR 0.81; 95% CI 0.46 to 1.40, P = 0.44). The mean estimated glomerular filtration rate (GFR) at 2 years, was 65.8 ml/min per 1.73 m2 body surface area in the TAS arm and 66.7 ml/min per 1.73 m2 in the TAS + B arm (P = 0.78). Blood pressure and cholesterol levels were similar in the two arms, and there was no evidence of a difference in the incidence of infection or malignancy. These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Webster AC, Playford EG, Higgins G, Chapman JR, Craig J (2004) Interleukin 2 receptor antagonists for kidney transplant recipient. Cochrane Database Syst Rev (1):CD003897
No authors listed (2004) Immunosuppressive therapy for renal transplantation in adults. National Institute for Health and Clinical Excellence
Smith JM, Nemeth TL, McDonald RA (2003) Current immunosuppressive agents: efficacy, side effects and utilization. Pediatr Clin North Am 50:1283–1300
Pape L, Strehlau J, Henne T, Latta K, Nashan B, Ehrich JH, Klempnauer J, Offner G (2002) Single centre experiences with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 17:276–280
Swiatecka-Urban A, Garcia C, Feuerstein D, Suzuki S, Devarajan P, Schechner R, Greenstein S, Tellis V, Kaskel F (2001) Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 16:693–696
Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, Gerbeau C, Chodoff L, Korn A, Hall M (2002) A multicenter, open-label pharmacokinetic/pharmacodynamic safety and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 74:961–966
Vester U, Kranz B, Testa G (2001) Efficacy and tolerability of interleukin-2 receptor blockage with basiliximab in pediatric renal transplant recipients. Pediatr Transplant 5:297–301
Grenda R, Watson A, Vondrak K, Webb NJA, Beattie J, Fitzpatrick M, Saleem MA, Trompeter R, Milford DV, Moghal NE, Hughes D, Perner F, Friman S, Van Damme-Lombaerts R, Janssen F (2006) A prospective, randomized, multicentre trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 6:1666–1672
No authors listed (2001) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use
Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K (2003) Interleukin-2 receptor antibodies in renal transplantation: meta-analysis of randomized trials. BMJ 326:789
Zimmerhackl LB, Jungraithmayr TC, Toenshoff B, Offner G, Faerber L, Mihatsch M (2007) Basiliximab for treatment of acute rejection: first prospective placebo controlled trial in children with 6 month protocol biopsy. A report of the Paediatric Basiliximab Study Group (abstract 154). Pediatr Transplant 11 [Suppl 1]:70
Trompeter R, Filler G, Webb NJA, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes D, Ehrich JHH, Klare B, Zacchello G, Brekke IB, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, Stolpe J (2002) Randomised multicentre study comparing tacrolimus with cyclosporin in renal transplantation. Pediatr Nephrol 17:141–149
Filler G, Trompeter RS, Webb NJA, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes DA, Offner G, Klare B, Zacchello G, Brekke I, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, Stolpe J (2002) GFR predicts graft survival in paediatric renal recipients: a randomised trial of tacrolimus vs cyclosporin microemulsion. Transplant Proc 34:1935–1938
Filler G, Webb NJA, Milford DV, Watson AR, Gellermann J, Tyden G, Grenda R, Vondrak K, Hughes D, Offner G, Griebel M, Brekke IB, McGraw M, Balzar E, Friman S, Trompeter R (2005) Four year data after paediatric renal transplantation: a randomised trial of tacrolimus vs cyclosporin microemulsion. Pediatr Transplant 9:498–503
Acknowledgements
This study was supported by an unrestricted educational grant from Astellas (formerly Fujisawa). The authors would like to thank all members of their transplant teams who contributed to data collection.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Webb, N.J.A., Prokurat, S., Vondrak, K. et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. Pediatr Nephrol 24, 177–182 (2009). https://doi.org/10.1007/s00467-008-0931-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-008-0931-x